About Us

Pushing the boundaries of RNAi, CRISPR, and testing technologies
Mirimus was established in 2010 with the goal of creating a scalable and cost effective pipeline for model generation by harnessing the power of RNAi and CRISPR technologies to develop animal models which are crucial for preclinical evaluation of new therapeutics. Through cutting edge technology, powerful predictive tools, and vital partnerships, Mirimus is paving the path to develop safer and more effective therapeutics by pin-pointing potential toxicities, validation, and disease modeling.

In 2020, responding to the Covid-19 pandemic, our team of experts mobilized their scientific expertise to develop a safe, regular, affordable, and non-invasive testing methodology. Our testing protocol, SalivaClear, is successful in detecting and monitoring SARS-COV-2 infection within communities around the country, allowing them to return to in-person operations. Mirimus’ goal is to facilitate the re-opening of the US economy by increasing access to testing and preventing large-scale outbreaks.

Our Team

Prem Premsrirut, MD, PhD

Founder & CEO

Veronica Andrews

Chief People Officer

David Eads

Chief Financial Officer

Sean Seibel

Chief Product & Technology Officer

Ana Vasileva, PhD

Senior Scientific Director

Hui-Ting Cheng, MS, PhD

Clinical Lab Director

Daniel Neumann

Associate Director of Operations

Giuseppe Militello, PhD

Associate Director of RNAi Therapeutics

James Kehler, PhD, VMD

VP of Translational Research

Our Advisors

Stephen Chang, PhD

Strategic Advisor

Scott W. Lowe, PhD

Founder, Strategic Advisor

Christof Fellmann, PhD


Stephen Elledge, PhD


Greg Hannon, PhD